{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443914293
| IUPAC_name = 6-(bis-(2,2,2-trifluoroethyl)amino)-4-trifluoromethyl-1''H''-quinolin-2-one
| image = LGD-2226.svg
| width = 250

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Investigational New Drug
| legal_status = 
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 328947-93-9
| ATC_prefix =  
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 11560224
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = RI376RM5MT
|  ChemSpiderID = 9734998
<!--Chemical data-->
| chemical_formula =  
| C=14 | H=9 | F=9 | N=2 | O=1 
| molecular_weight = 392.219 g/mol
| smiles = FC(F)(F)c(c2)c1cc(N(CC(F)(F)F)CC(F)(F)F)ccc1[nH]c2=O
|  StdInChI = 1S/C14H9F9N2O/c15-12(16,17)5-25(6-13(18,19)20)7-1-2-10-8(3-7)9(14(21,22)23)4-11(26)24-10/h1-4H,5-6H2,(H,24,26)
|  StdInChIKey = ULBPQWIGZUGPHU-UHFFFAOYSA-N
}}

'''LGD-2226''' is an investigational [[selective androgen receptor modulator]] (SARM),<ref>van Oeveren A, Motamedi M, Mani NS, Marschke KB, López FJ, Schrader WT, Negro-Vilar A, Zhi L. Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. ''Journal of Medicinal Chemistry''. 2006 Oct 19;49(21):6143-6. {{DOI|10.1021/jm060792t}} {{PMID|17034117}}</ref> which is being developed for treatment of [[muscle]] wasting and [[osteoporosis]].<ref>Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). ''Drug Discovery Today''. 2007 Mar;12(5-6):241-8. {{DOI|10.1016/j.drudis.2007.01.003}} {{PMID|17331889}}</ref> 

LGD-2226 is an orally active, potent and selective agonist for androgen receptors which was shown to have [[anabolic]] effects in both muscle and bone tissue, but with considerably less effects on [[prostate gland|prostate]] weight and [[lutenizing hormone]] levels than [[testosterone]].<ref>Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, López FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. ''Endocrinology''. 2007 Jan;148(1):363-73. {{DOI|10.1210/en.2006-0793}} {{PMID|17023534}}</ref><ref>Hong MH, Sun H, Jin CH, Chapman M, Hu J, Chang W, Burnett K, Rosen J, Negro-Vilar A, Miner JN. Cell-specific activation of the human skeletal alpha-actin by androgens. ''Endocrinology''. 2008 Mar;149(3):1103-12. {{DOI|10.1210/en.2007-0530}} {{PMID|18063690}}</ref>

Selective androgen receptor modulators may also be used by athletes to assist in training and increase physical stamina and fitness, potentially producing effects similar to [[anabolic steroid]]s but with significantly less side effects. For this reason, SARMs have already been banned by the [[World Anti-Doping Agency]] since January 2008 despite no drugs from this class yet being in clinical use, and blood tests for all known SARMs are currently being developed,<ref>Thevis M, Kohler M, Schlörer N, Kamber M, Kühn A, Linscheid MW, Schänzer W. Mass spectrometry of hydantoin-derived selective androgen receptor modulators. ''Journal of Mass Spectrometry''. 2008 May;43(5):639-50. {{DOI|10.1002/jms.1364}} {{PMID|18095383}}</ref><ref>Thevis M, Kohler M, Thomas A, Maurer J, Schlörer N, Kamber M, Schänzer W. Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS/MS. ''Analytical and Bioanalytical Chemistry''. 2008 May;391(1):251-61. {{DOI|10.1007/s00216-008-1882-6}} {{PMID|18270691}}</ref> including LGD-2226.<ref>Thevis M, Kohler M, Maurer J, Schlörer N, Kamber M, Schänzer W. Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis. ''Rapid Communications in Mass Spectrometry''. 2007;21(21):3477-86. {{DOI|10.1002/rcm.3247}} {{PMID|17985352}}</ref>

== References ==
{{Reflist}}


{{Androgenics}}

[[Category:Hormonal agents]]
[[Category:Quinolines]]
[[Category:Lactams]]
[[Category:Organofluorides]]
[[Category:Selective androgen receptor modulators]]
[[Category:Trifluoromethyl compounds]]